Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Investors Lab
  • Published:

Is there balm in Gilead?

Nature Biotechnology volume 24, page 1478 (2006)Cite this article

Access through your institution
Buy or subscribe

If ever an area of biotech exemplified the investor's mantra 'buyer beware', then anti-infectives would be it. For example, of the 16 publicly traded companies with some sort of antibiotic development program listed on p. 1478, 14 are newer and unprofitable; investors must therefore be careful not to let the science story obscure whether the money will run out before the pivotal trials are done. For the remaining profitable companies, investors must not overpay. But there are opportunities for cheaper shares and good investment candidates if you are both prepared and patient.

The importance of money

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Author notes

  1. Tom Jacobs is co-founder of Complete Growth Investor, http://www.completegrowth.com, a stock service for individual investors. Tom held no position in any of the companies mentioned here at time of writing.

    • Tom Jacobs
Authors
  1. Tom Jacobs
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobs, T. Is there balm in Gilead?. Nat Biotechnol 24, 1478 (2006). https://doi.org/10.1038/nbt1206-1478

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt1206-1478

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing